Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chang'an II Recipe is a traditional Chinese medicine (TCM) herbal prescription derived from the classical formula Tong-Xie-Yao-Fang. It is primarily used for the treatment of irritable bowel syndrome (IBS), particularly in cases associated with liver-qi stagnation and spleen deficiency syndromes. Preclinical studies indicate that it exerts anti-inflammatory, immunomodulatory, and anti-anxiety effects. In animal models of post-inflammation IBS (PI-IBS), it has been shown to repair intestinal mucosal barrier damage by modulating immune cell ratios (CD4+/CD8+), reducing pro-inflammatory cytokines such as IL-1β, increasing anti-inflammatory cytokines like IL-4, and improving behavioral symptoms related to anxiety and depression. The mechanism may also involve inhibition of MLCK-mediated pathways contributing to intestinal barrier protection[1][3][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chang'an II Recipe.